country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-170592

Copy Link Print Information

dALK-3

dALK-3 is an EML4-ALK inhibitor with an IC₅₀ of 13.1 nM against the human target. dALK-3 induces proteasomal degradation of EML4-ALK through components of the ubiquitin-proteasome system. dALK-3 exhibits antiproliferative activity against cancer cells. dALK-3 can be used in research related to non-small cell lung cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₃₉H₄₅ClN₇O₅P
Molecular Weight:758.25

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

dALK-3 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
NCI-H3122	GI50	0.004 μM	Antiproliferative activity against human H3122 non-small-cell lung cancer cells with EML4-ALK fusion incubated for 72 hrs assessed by CellTiter-Glo assay. Antiproliferative activity against human H3122 non-small-cell lung cancer cells with EML4-ALK fusion incubated for 72 hrs assessed by CellTiter-Glo assay.	39681169
NCI-H3122	GI50	0.002 μM	Antiproliferative activity against RNF126-depleted human H3122 non-small-cell lung cancer cells with EML4-ALK fusion incubated for 72 hrs assessed by CellTiter-Glo assay. Antiproliferative activity against RNF126-depleted human H3122 non-small-cell lung cancer cells with EML4-ALK fusion incubated for 72 hrs assessed by CellTiter-Glo assay.	39681169
NCI-H3122	DC₅₀	0.182 μM	Dose-dependent degradation of EML4-ALK protein in human H3122 non-small-cell lung cancer cells with EML4-ALK fusion measured via western blotting. Dose-dependent degradation of EML4-ALK protein in human H3122 non-small-cell lung cancer cells with EML4-ALK fusion measured via western blotting.	39681169

In Vitro

Anti-cancerOthers

Anti-cancer

dALK-3 (72 h) potently inhibits H3122 cell proliferation with a GI₅₀ of 0.004 μM, and this antiproliferative activity remains unchanged in RNF126-knockdown H3122 cells^[1].
dALK-3 (1-10 μM; 8 h) induces dose-dependent proteasomal degradation of EML4-ALK in H3122 cells with a DC₅₀ of 0.182 μM, and inhibits ALK downstream signaling pathways including STAT3 and AKT^[1].
dALK-3 (1 μM; 24 h)-induced EML4-ALK degradation in H3122 cells depends on the proteasome pathway^[1].

Others

dALK-3 (1 μM) exhibits high selectivity for purified ALK kinase, moderate inhibitory activity against purified EGFR^L858R and ROS kinases, and only weak activity against purified IGF-1R and IR kinases^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

H3122 non-small-cell lung cancer cells with EML4-ALK fusion
Concentration:

1, 3, 10 μM
Incubation Time:

8 h
Result:

Induced dose-dependent degradation of EML4-ALK protein, achieving 82% degradation at 10 μM after 8 h.
Exhibited a DC₅₀ of 0.182 μM and a Dₘₐₓ of 78.2% for ALK degradation.
Reduced p-ALK levels, and at 1 μM, inhibited p-STAT3 more effectively than brigatinib, while inhibiting p-AKT to a similar extent as brigatinib.

Related Protocols :

Cell Viability Determination by MTT Colorimetric Assay

Chemical Information

Molecular Weight 758.25
Formel C₃₉H₄₅ClN₇O₅P
SMILES

ClC1=C(NC2=CC=CC=C2P(C)(C)=O)N=C(NC3=C(OC)C=C(N4CCC(N5CCN(C(/C=C/C(C6=CC=C(OC)C=C6)=O)=O)CC5)CC4)C=C3)N=C1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yu N, et al. Design and evaluation of anaplastic lymphoma kinase degraders using a covalent fumarate handle. Bioorganic & medicinal chemistry letters. 2025 Mar 01;117:130075. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

dALK-3